Interaction of 14-3-3 proteins with the estrogen receptor alpha F domain provides a drug target interface.
De Vries-van Leeuwen, I.J., da Costa Pereira, D., Flach, K.D., Piersma, S.R., Haase, C., Bier, D., Yalcin, Z., Michalides, R., Feenstra, K.A., Jimenez, C.R., de Greef, T.F., Brunsveld, L., Ottmann, C., Zwart, W., de Boer, A.H.(2013) Proc Natl Acad Sci U S A 110: 8894-8899
- PubMed: 23676274 
- DOI: 10.1073/pnas.1220809110
- Primary Citation of Related Structures:  
4JC3, 4JDD - PubMed Abstract: 
Estrogen receptor alpha (ERα) is involved in numerous physiological and pathological processes, including breast cancer. Breast cancer therapy is therefore currently directed at inhibiting the transcriptional potency of ERα, either by blocking estrogen production through aromatase inhibitors or antiestrogens that compete for hormone binding ...